IDiyas

For the Inventor, By the Inventor

Shizuoka, Japan

Hiroharu Matsuoka

USPTO Granted Patents = 12

Average Co-Inventor Count = 3.6

ph-index = 5

Forward Citations = 50(Granted Patents)


Location History:

  • Shizuoka, JP (1994 - 2011)
  • Gotenba, JP (2004 - 2011)

Company Filing History:

goldMedal12 out of 947 
 
Chugai Seiyaku Kabushiki Kaisha
 patents

Years Active: 1994-2011

Loading Chart...
12 patents (USPTO):
1. 8048897 - Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes (2011-11-01),
2. 7943748 - Glucitol derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes (2011-05-17),
3. 7612070 - Indole derivative having heterocycle and mono- or diazaindole derivative (2009-11-03),
4. 7553969 - Substituted phenethylamine derivatives (2009-06-30),
5. 7396858 - Biguanide derivative and therapeutic agent for diabetes containing the same (2008-07-08),
6. 7018981 - Cyclic motilin receptor antagonists (2006-03-28),
7. 6875770 - Indole derivative having heterocycle and mono- or diazaindole derivative (2005-04-05),
8. 6720433 - Ethylamine derivatives (2004-04-13),
9. 6673797 - Heterocyclic indole derivatives and mono- or diazaindole derivatives (2004-01-06),
10. 6586630 - Ethylamine derivatives (2003-07-01),
11. 6559149 - Methotrexate derivatives (2003-05-06),
12. 5354753 - Methotrexate derivative (1994-10-11),

Title: Innovations in Diabetes Treatment by Hiroharu Matsuoka

Introduction

Hiroharu Matsuoka is a prominent inventor based in Shizuoka, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of therapeutic agents for diabetes. With a total of 12 patents to his name, Matsuoka's work focuses on innovative compounds that aim to improve the management of blood sugar levels.

Latest Patents

Matsuoka's latest patents include a cyclohexane derivative and a glucitol derivative, both designed to reduce blood sugar levels. The cyclohexane derivative is characterized by its long-lasting drug activity, metabolic stability, and safety. It is intended for the prevention or treatment of hyperglycemia-related diseases, including both types of diabetes and obesity. The glucitol derivative also shares similar properties and is aimed at providing effective treatment options for patients suffering from diabetes and its complications.

Career Highlights

Matsuoka is currently associated with Chugai Seiyaku Kabushiki Kaisha, a leading pharmaceutical company in Japan. His work at Chugai has allowed him to collaborate with other talented professionals in the field, further enhancing the impact of his inventions.

Collaborations

Some of Matsuoka's notable coworkers include Tsutomu Sato and Nobuaki Kato. Their collaborative efforts contribute to the innovative research and development of new therapeutic agents.

Conclusion

Hiroharu Matsuoka's contributions to diabetes treatment through his innovative patents highlight the importance of ongoing research in medicinal chemistry. His work continues to pave the way for new therapeutic options that can significantly improve the quality of life for individuals with diabetes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…